MILWAUKEE, Oct. 9, 2013 (GLOBE NEWSWIRE) -- We are investigating possible securities fraud claims against ARIAD Pharmaceuticals Inc. resulting from inaccurate statements ARIAD made regarding its PACE trial of Iclusig ®.
Click here to learn more about the investigation: http://www.ademilaw.com/case/ariad-pharmaceuticals-inc or call Guri Ademi toll-free at 866-264-3995. There is no cost or obligation to you.
Our investigation focuses on the extent to which ARIAD issued false and misleading statements regarding its financial statement, past and future business performance and prospects. Specifically, ARIAD failed to disclose that its PACE trial of Iclusig ® (ponatinib) was showing (i) serious arterial thrombosis occurred in 11.8% of Iclusig-treated patients: cardiovascular events 6.2%, cerebrovascular events 4.0% and peripheral vascular events 3.6% compared to 8.0% after 11 months of follow up reflected in the current U.S. prescribing information, and (ii) serious venous occlusion occurred in 2.9% of Iclusig-treated patients, compared to 2.2% in the current U.S. prescribing information. Non-serious and serious arterial and venous adverse events combined occurred in approximately 20% of Iclusig-treated patients. On October 9, 2013 ARIAD announced that the U.S. Food & Drug Administration has placed a partial clinical hold on all new patient enrollment in clinical trials of Iclusig.
If you wish to obtain additional information or have information about ARIAD, please contact Guri Ademi either at gademi@ademilaw.com or toll-free: 866-264-3995, http://www.ademilaw.com/case/ariad-pharmaceuticals-inc.
We specialize in securities fraud and shareholder litigation. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes.